Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium Receives Day 180 List of Outstanding Issues From the CHMP for Defibrotide MAA

VILLA GUARDIA, Italy, May 4, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has received the Day 180 List of Outstanding Issues (the "LoOIs") from the...
May 02, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium Appoints PharmaSwiss, S.A. as Exclusive Distributor of Defibrotide in Central and Eastern European Countries

VILLA GUARDIA (COMO), Italy, May 2, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) today announced the appointment of PharmaSwiss S.A., a division of Valeant Pharmaceuticals International,...
April 02, 2012 07:36 ET | Source: Gentium S.p.A.

Gentium Hosts Symposium on Defibrotide at EBMT Annual Meeting

VILLA GUARDIA (COMO), Italy, April 2, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the Company's lead product, Defibrotide, was the subject of a...
March 27, 2012 07:00 ET | Source: Gentium S.p.A.

Gentium Reports Fourth Quarter and Year End 2011 Financial Results

Defibrotide usage increased by 28% to EUR 16.89 million (US$ 21.91 million) Total product sales of EUR 21.73 million (US$ 28.19 million) Net income of EUR 2.71 million (US$ 3.52...
March 20, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium to Review Fourth Quarter and Year End 2011 Financial Results

VILLA GUARDIA (COMO), Italy, March 20, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the Company will publish financials for the fourth quarter and year...
March 06, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium Appoints Dr. Carin Heringa as Senior Vice President and Scientific Director

VILLA GUARDIA, Italy, March 6, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that Dr. Carin Heringa, Head of Global Medical Affairs of Gentium, has been newly...
February 27, 2012 07:30 ET | Source: Gentium S.p.A.

The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients

VILLA GUARDIA, Italy, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that results from a Phase III randomised controlled trial which evaluated...
February 21, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium Responds to the EMA's Day 120 List of Questions for Defibrotide MAA

VILLA GUARDIA, Italy, Feb. 21, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has submitted its response to the Day 120 List of Questions (the "LoQs")...
January 09, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium Appoints Swedish Orphan Biovitrum AB as Exclusive Distributor of Defibrotide in Nordic and Baltic Territories

VILLA GUARDIA (COMO), Italy, Jan. 9, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced the appointment of the Swedish Orphan Biovitrum A.B., (Sobi) (Stockholm:SOBI) as the exclusive...
December 29, 2011 07:30 ET | Source: Gentium S.p.A.

Gentium Provides Update on MAA Process for Defibrotide in Europe

VILLA GUARDIA, Italy, Dec. 29, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today provided an update on the European Marketing Authorization Application for Defibrotide (the...